<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="109368">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02036164</url>
  </required_header>
  <id_info>
    <org_study_id>COA-CREC 002/2013</org_study_id>
    <secondary_id>20140106001</secondary_id>
    <nct_id>NCT02036164</nct_id>
  </id_info>
  <brief_title>Adjuvant Chemotherapy for Locally Advanced Cervical Cancer</brief_title>
  <acronym>ACT-LACC</acronym>
  <official_title>Randomized Controlled Trial Comparing Concurrent Chemoradiation Versus Concurrent Chemoradiation Followed by Adjuvant Chemotherapy in Locally Advanced Cervical Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Siriwan Tangjitgamol, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Research Council of Thailand</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Navamindradhiraj University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chiang Mai University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chulalongkorn University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Prince of Songkla University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bhumibol Adulyadej Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Lopburi Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ubonratchathani Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Udonthani Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chonburi Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Lampang Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Health Intervention and Technology Assessment Program</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Navamindradhiraj University</source>
  <oversight_info>
    <authority>Thailand: Ethical Committee</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Data of survival benefit from adjuvant chemotherapy (ACT) after concurrent chemoradiation
      (CCRT) for locally advanced cervical cancer (LACC) are still limited and inconsistent. We
      will investigate if ACT has survival benefit over CCRT alone.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Concurrent chemoradiation (CCRT) is the standard treatment for cervical cancer of FIGO stage
      IIB-IVA or so called locally advanced cervical cancer (LACC). However, failure rate after
      treatment is still as high as 30% to 40%.

      This is a multi-center randomized controlled trial which evaluates whether adjuvant
      chemotherapy (ACT) after CCRT will improve treatment outcome comparing to CCRT alone.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">January 2017</completion_date>
  <primary_completion_date type="Anticipated">June 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>3 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>3-year progression free survival</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>3 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>3-year overall survival</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Response rate</measure>
    <time_frame>4 months after completion of CCRT</time_frame>
    <safety_issue>No</safety_issue>
    <description>Response rate will be assessed at 4 months after completion of CCRT (expected to be at 4 months after CCRT in the control arm or at 1 month after completion of adjuvant chemotherapy in the study arm)</description>
  </other_outcome>
  <other_outcome>
    <measure>Cost-utility analysis</measure>
    <time_frame>Cost of treatment and quality of life will be assessed at baseline, completion of CCRT, q month for 3 months after CCRT, after each cycle of ACT, 2 years after completion of treatment, and when there are tumor presistence, progression or recurrence</time_frame>
    <safety_issue>No</safety_issue>
    <description>Cost and quality of life</description>
  </other_outcome>
  <other_outcome>
    <measure>Adverse event</measure>
    <time_frame>up to 6 months after treatment</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Adverse events occurred during and after treatment</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Uterine Cervical Cancer</condition>
  <condition>(FIGO Stage IIB-IVA)</condition>
  <arm_group>
    <arm_group_label>Concurrent chemoradiation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Radiation: Radiation Therapy
External beam pelvic radiotherapy (45-50.4 Gy in 1.8 Gy fractions) delivered by Linear accelerator machine
Vaginal brachytherapy for 4-5 fractions
Chemotherapy: Cisplatin
- Cisplatin 40 mg/m2 i.v., q wk, 6 cycles during radiotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Concurretn chemoradiation plus adjuvant chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Radiation: Radiation Therapy
External beam pelvic radiotherapy (45-50.4 Gy in 1.8 Gy fractions) delivered by Linear accelerator machine
Vaginal brachytherapy for 4-5 fractions
Chemotherapy: Cisplatin, palcitaxel, carboplatin
Cisplatin 40 mg/m2 i.v., q wk, 6 cycles during radiotherapy
Paclitaxel 175 mg/m2 i.v. q 4 wks, 3 cycles starting 4 week after completion of CCRT
Carboplatin AUC 5 i.v. q 4 wks, 3 cycles given together with paclitaxel</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Pelvic radiation</intervention_name>
    <description>Radiation:
Pelvic radiation 1.8 Gy/ day, 5 days/ week, 6 weeks
Brachytherapy 30-35 Gy for 4-5 times</description>
    <arm_group_label>Concurrent chemoradiation</arm_group_label>
    <arm_group_label>Concurretn chemoradiation plus adjuvant chemotherapy</arm_group_label>
    <other_name>External beam pelvic radiation therapy and brachytherapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Cisplatin 40 mg/m2 i.v.</description>
    <arm_group_label>Concurrent chemoradiation</arm_group_label>
    <arm_group_label>Concurretn chemoradiation plus adjuvant chemotherapy</arm_group_label>
    <other_name>Drugs:</other_name>
    <other_name>- Cisplatin</other_name>
    <other_name>- Kemoplat®</other_name>
    <other_name>- Platin®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Paclitaxel 175 mg m2 i.v.</description>
    <arm_group_label>Concurretn chemoradiation plus adjuvant chemotherapy</arm_group_label>
    <other_name>- Intaxel®</other_name>
    <other_name>- Anzatax®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Carboplatin AUC 5 i.v.</description>
    <arm_group_label>Concurretn chemoradiation plus adjuvant chemotherapy</arm_group_label>
    <other_name>- Carboplatin®</other_name>
    <other_name>- Kemocarb®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18-70 years

          -  Cervical cancer FIGO stage IIB-IVA

          -  Histopathology of squamous cell carcinoma, adenocarcinoma, or adenosquamous cell
             carcinoma

          -  ECOG performance status 0-2

          -  No history of other cancer except basal cell carcinoma

          -  Adequate bone marrow function (WBC &gt; or = 3,000/mm3, granulocytes &gt; or = 1,500/mm3,
             platelet count &gt; or = 100,000/mm3)

          -  Bilirubin &lt; 1.5 folds, SGOT/ SGPT &lt; 1.5 folds of normal limit, creatinine clearance &gt;
             or = 40 mg/dl

          -  Consent to participate

        Exclusion Criteria:

          -  Para-aortic lymph node enlargement &gt; 1 cm or suspicious for cancer metastasis from CT
             or MRI

          -  Adnexal mass from physical examination or imaging study

          -  Chronic illnesses e.g. renal failure/ impairment, peripheral or central neuropathy,
             uncontrolled diabetes mellitus, or HIV infection.

          -  Pregnancy or lactation
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Siriwan - Tangjitgamol, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Navamindradhiraj University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kanyarat - Katanyoo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Navamindradhiraj University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Siriwan - Tangjitgamol, MD</last_name>
    <phone>66-86-3841431</phone>
    <phone_ext>-</phone_ext>
    <email>siriwanonco@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kanyarat - Katanyoo, MD</last_name>
    <phone>66-89-1529152</phone>
    <phone_ext>-</phone_ext>
    <email>kankatanyoo@edu.vajira.ac.th</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Obstetrics and Gynecology, Department of Radiology, Epidemiology Unit, Navamindradhiraj University</name>
      <address>
        <city>Bangkok</city>
        <zip>10300</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Siriwan Tangjitgamol, MD</last_name>
      <phone>66-86-3841431</phone>
      <email>siriwanonco@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>Kanyarat Katanyoo, MD</last_name>
      <phone>66-89-1529152</phone>
      <email>kankatanyoo@edu.vajira.ac.th</email>
    </contact_backup>
    <investigator>
      <last_name>Siriwan Tangjitgamol, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kanyarat Katanyoo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Busaba Supawattanabodee, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sumonmal Manusirivithaya, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bhumibol Adulyadej Hospital</name>
      <address>
        <city>Bangkok</city>
        <zip>10220</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Thanomsiri SoonThornthum, MD</last_name>
      <phone>66-81-6896927</phone>
      <email>tan270314@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>Apiradee Kridakara, MD</last_name>
      <phone>66-86-3671487</phone>
      <email>akrid7@hotmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Thanomsiri Soonthornthum, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Apiradee Kridakara, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Radiology, Department of Obsterics and Gynecology, Chulalongkorn University</name>
      <address>
        <city>Bangkok</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Chonlakiet Khorprasert, MD</last_name>
      <phone>66-89-1374951</phone>
      <email>chonlakiet@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Chonlakiet Khorprasert, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Prasert Lertsanguansinchai, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Wichai Termrungruanglert, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>John Kavanagh, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Health Intervention and Technology Assessment Program</name>
      <address>
        <city>Bangkok</city>
        <zip>11000</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yot Teerawattananon, MD</last_name>
      <phone>66-84-6760080</phone>
      <email>yot.t@hitap.net</email>
    </contact>
    <investigator>
      <last_name>Yot Teerawattananon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Radiology, Department of Obstetrics and Gynecology, Chiang Mai University</name>
      <address>
        <city>Chiang Mai</city>
        <zip>50200</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ekkasit Tharavijitkul, MD</last_name>
      <phone>966-89-4338709</phone>
      <email>paan_31@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Ekkasit Tharavijitkul, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vichan Lordvithaya, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jatupol Srisomboon, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chonburi Cancer Hospital</name>
      <address>
        <city>Chonburi</city>
        <zip>20000</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Chokaew Tovanabutra, MD</last_name>
      <phone>66-81-4726633</phone>
      <email>chokaewt@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Chokaew Tovanabutra, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Napat Injumpa, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lampang Cancer Hospital</name>
      <address>
        <city>Lampang</city>
        <zip>52000</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tussawan Asakit, MD</last_name>
      <phone>66-81-6715013</phone>
      <email>tussawan_a1@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Tussawan Asakit, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kannika Paengchit, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lopburi Cancer Hospital</name>
      <address>
        <city>Lopburi</city>
        <zip>15000</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jirasak Sukhaboon, MD</last_name>
      <phone>66-89-7970600</phone>
      <email>fodjiji@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Jirasak Sukhaboon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Panit Chiewaratanapong, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Obstetrics and Gynecology, Department of Radiology, Prince of Songkla University</name>
      <address>
        <city>Songkla</city>
        <zip>90110</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jitti Hanprasertpong, MD</last_name>
      <phone>66-89-6540214</phone>
      <email>hjitti@medicine.psu.ac.th</email>
    </contact>
    <investigator>
      <last_name>Jitti hanprasertpong</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Duangjai Sangthawan</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ubonratchathani Cancer Hospital</name>
      <address>
        <city>Ubonratchathani</city>
        <zip>34000</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Taywin Chottetanaprasith, MD</last_name>
      <phone>66-81-9359756</phone>
      <email>taywinc@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Taywin Chottetanaprasith, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Metee Wongsena, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Udonthani Cancer Hopital</name>
      <address>
        <city>Udonthani</city>
        <zip>41330</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Somkit Penpattanagul, MD</last_name>
      <phone>66-86-0442177</phone>
      <email>skpptng@yahoo.co.th</email>
    </contact>
    <investigator>
      <last_name>Somkit Penpattanagul, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 12, 2014</lastchanged_date>
  <firstreceived_date>January 8, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Navamindradhiraj University</investigator_affiliation>
    <investigator_full_name>Siriwan Tangjitgamol, MD</investigator_full_name>
    <investigator_title>Doctor</investigator_title>
  </responsible_party>
  <keyword>Locally advanced cervical cancer</keyword>
  <keyword>Concurrent chemoradiation</keyword>
  <keyword>Adjuvant chemotherapy</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
